Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;8(7):570-582.
doi: 10.1016/j.trecan.2022.03.002. Epub 2022 Mar 31.

Ecology and evolution of dormant metastasis

Affiliations
Free article
Review

Ecology and evolution of dormant metastasis

María Teresa Blasco et al. Trends Cancer. 2022 Jul.
Free article

Abstract

Genetic studies suggest that sequential dissemination from a primary metastasis, usually at the bone, is a major route of metastatic progression in early, radically resected cancer. Disseminated tumor cells (DTCs) can likely infiltrate but not grow, and may remain dormant once disseminated for extended intervals (from months to decades). The stationary nature of DTCs prevents them from being successfully treated as an asymptomatic residual disease in the adjuvant setting; critically, they can eventually relapse, adapt, and develop therapy resistance, causing incurable overt metastasis. Metastatic lesions usually first appear in one tissue, which invigorates metastatic cells for further dissemination to other organs, with a fatal outcome. Clinical and genetic data now indicate that metastatic lesions in one organ can seed secondary metastases in other organs: in other words, metastasis arising from metastasis. Herein we discuss recent insight into metastasis cell dormancy mechanisms, survival, communication with the local microenvironment, and eventual changes that endow DTCs with the capacity to expand and colonize to other metastatic sites.

Keywords: adaptation; dormancy; evolution; metastasis; microenvironment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.R.G. declares shares of Inbiomotion and has patents and patents pending related to MAF biomarker work.

Publication types

MeSH terms

LinkOut - more resources